FY2025 EPS Estimates for Precigen Lowered by HC Wainwright

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Equities researchers at HC Wainwright decreased their FY2025 earnings estimates for shares of Precigen in a research report issued to clients and investors on Thursday, May 15th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings per share of ($0.37) for the year, down from their prior forecast of ($0.29). HC Wainwright has a "Buy" rating and a $6.00 price target on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen's Q4 2025 earnings at ($0.04) EPS, FY2026 earnings at ($0.01) EPS, FY2028 earnings at $0.37 EPS and FY2029 earnings at $0.62 EPS.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%. The company had revenue of $1.34 million during the quarter, compared to the consensus estimate of $0.50 million.

Other equities analysts have also recently issued reports about the company. Wall Street Zen cut Precigen from a "hold" rating to a "sell" rating in a research note on Saturday. Cantor Fitzgerald reissued an "overweight" rating on shares of Precigen in a report on Thursday, May 15th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, Precigen has a consensus rating of "Moderate Buy" and an average price target of $7.00.

Precigen Stock Down 1.4%

NASDAQ:PGEN traded down $0.02 during trading hours on Monday, hitting $1.37. 1,408,452 shares of the company traded hands, compared to its average volume of 1,328,964. The firm's 50-day simple moving average is $1.46 and its 200-day simple moving average is $1.32. Precigen has a one year low of $0.65 and a one year high of $2.17. The company has a market cap of $404.40 million, a PE ratio of -2.49 and a beta of 1.82.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PGEN. Parkman Healthcare Partners LLC purchased a new position in Precigen during the 1st quarter valued at about $4,755,000. Iridian Asset Management LLC CT grew its holdings in shares of Precigen by 38.8% during the fourth quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company's stock worth $5,871,000 after purchasing an additional 1,465,962 shares in the last quarter. LexAurum Advisors LLC lifted its position in Precigen by 151.9% in the 4th quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company's stock worth $775,000 after buying an additional 417,055 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in Precigen by 3.8% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 11,276,000 shares of the biotechnology company's stock worth $16,801,000 after buying an additional 410,595 shares during the last quarter. Finally, Nuveen LLC bought a new stake in Precigen in the 1st quarter worth approximately $275,000. Hedge funds and other institutional investors own 33.51% of the company's stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.